RAINBOW - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.2

📊 Analysis: RAINBOW shows moderate potential for intraday trading. RSI at 42.2 indicates mildly oversold conditions, while MACD (-3.82) is negative, suggesting short-term bearishness. Current price (₹1,315) is below both 50 DMA (₹1,362) and 200 DMA (₹1,403), reflecting weakness. Volume (86K) is slightly below weekly average (93K), limiting intraday momentum strength.

💡 Optimal Buy Price: ₹1,310–₹1,320 if price stabilizes near support.

🎯 Profit Exit Levels: ₹1,340–₹1,355 (near 50 DMA resistance).

🛡️ Stop-Loss: ₹1,300 (below short-term support).

⏱️ Intraday Exit Guidance: If already holding, consider exiting near ₹1,340–₹1,355 if momentum weakens or volume fails to support breakout. Exit immediately if price drops below ₹1,300 intraday.

Positive

• 📈 Strong ROCE: 18.3% indicates efficient capital utilization.
• 📊 ROE at 16.7%: Reflects healthy equity returns.
• 💸 DII holding increased: +2.02% shows domestic institutional confidence.
• 📈 EPS at ₹24.3: Supports earnings base.

Limitation

• ⚠️ High P/E ratio: 54.2 vs industry PE of 51.8 highlights relative overvaluation.
• 📉 Price below DMA levels: Trading below 50 & 200 DMA indicates weakness.
• 🔻 PEG ratio at 3.04: Suggests expensive growth expectations.
• 📉 Volume below average: May limit intraday momentum strength.

Company Negative News

• 📉 FII holding reduced: -1.75% shows foreign investor caution.
• 💸 Quarterly PAT decline: ₹73.2 Cr vs ₹51.7 Cr, -5.39% variance.

Company Positive News

• 📊 Sequential PAT growth: ₹73.2 Cr vs ₹51.7 Cr shows improvement over previous quarter.
• 📈 DII holding increased: +2.02% reflects strong domestic institutional confidence.

Industry

• 🏥 Industry PE: 51.8, close to RAINBOW’s 54.2, suggests fair valuation but limited upside.
• 📊 Healthcare sector demand: Sector remains resilient, offering long-term opportunities though intraday momentum is weak.

Conclusion

⚖️ RAINBOW is a moderately weak intraday candidate today due to negative MACD, oversold RSI, and price trading below DMA levels. Optimal buy zone is ₹1,310–₹1,320 with profit exits near ₹1,340–₹1,355. Traders should maintain tight stop-losses at ₹1,300 and avoid aggressive intraday positioning.

Would you like me to extend this into a peer benchmarking overlay with other healthcare/hospital stocks (like Apollo Hospitals, Narayana Hrudayalaya, Fortis) for intraday comparison, or prepare a sector rotation basket for swing setups in healthcare services?